Category: MIL-OSI

Source: The Conversation – Global Perspectives – By Angélica Durán-Martínez, Associate Professor of Political Science, UMass Lowell

The death of a major cartel boss in Mexico has unleashed a violent backlash in which members of the criminal group have paralyzed some cities through blockades and attacks on property and security forces.

At least 73 people have died as a result of the operation to capture Nemesio Oseguera Cervantes, or “El Mencho.” The head of the Jalisco New Generation Cartel was seriously wounded during a firefight with authorities on Feb. 22, 2026. He later died in custody.

As an expert in criminal groups and drug trafficking in Latin America who has been studying Mexico’s cartels for two decades, I see the violent aftermath of the operation as part of a pattern in which Mexican governments have opted for high-profile hits that often lead only to more violence without addressing the broader security problems that plague huge swaths of the country.

Who was ‘El Mencho’?

Like many other figures involved in Mexico’s drug trafficking, Oseguera Cervantes started at the bottom and made his way up the ranks. He spent some time in prison in the U.S., where he may have forged alliances with criminal gangs before being deported back to Mexico in 1997. There, he connected with the Milenio Cartel, an organization that first allied, and then fought with, the powerful Sinaloa Cartel.

Most of the information available points to the Jalisco New Generation Cartel forming under El Mencho around 2010, following the killing of Ignacio “Nacho” Coronel Villarreal, a Sinaloa Cartel leader and main link with the Milenio Cartel.

Since 2015, Jalisco New Generation Cartel has been known for its blatant attacks against security forces in Mexico – such as gunning down a helicopter in that year. And it has expanded its presence both across Mexico and internationally.

In Mexico, it is said to have a presence in all states. In some, the cartel has a direct presence and very strong local networks. In others, it has cultivated alliances with other trafficking organizations.

Besides drug trafficking, the Jalisco New Generation Cartel is also engaged in oil theft, people smuggling and extortion. As a result, it has become one of the most powerful cartels in Mexico.

What impact will his death have on the cartel?

There are a few potential scenarios, and a lot will depend on what succession plans Jalisco New Generation had in the event of Oseguera Cervantes’ capture or killing.

In general, these types of operations – in which security forces take out a cartel leader – lead to more violence, for a variety of reasons.

Mexicans have already experienced the immediate aftermath of Oseguera Cervantes’ death: retaliation attacks, blockades and official attempts to prevent civilians from going out. This is similar to what occurred after the capture of drug lord Ovidio Guzmán López in Sinaloa in 2019 and his second capture in 2023.

Violence flares in two ways following such high-profile captures and killings of cartel leaders.

In the short term, there is retaliation. At the moment, members of the Jalisco New Generation Cartel are seeking revenge against Mexico’s security forces and are also trying to assert their regional authority despite El Mencho’s death.

These retaliatory campaigns tend to be violent and flashy. They include blockades as well as attacks against security forces and civilians.

Then there is the longer-term violence associated with any succession. This can take the form of those who are below Oseguera Cervantes in rank fighting for control. But it can also result from rival groups trying to take advantage of any leadership vacuum.

The level and duration of violence depend on a few factors, such as whether there was a succession plan and what kind of alliances are in place with other cartels. But generally, operations in which a cartel boss is removed lead to more violence and fragmentation of criminal groups.

Of course, people like Oseguera Cervantes who have violated laws and engaged in violence need to be captured. But in the long run, that doesn’t do anything to dismantle networks of criminality or reduce the size of their operations.

What is the current state of security in Mexico?

The upsurge in violence after Oseguera Cervantes’ killing occurs as some indicators in Mexico’s security situation seemed to be improving.

For example, homicide rates declined in 2025 – which is an important indicator of security.

But other measures are appalling. Disappearances are still unsettlingly high. The reality that many Mexicans experience on the ground is one where criminal organizations remain powerful and embedded in the local ecosystems that connect state agents, politicians and criminals in complex networks.

Criminal organizations are engaged in what we academics call “criminal governance.” They engage in a wide range of activities and regulate life in communities – sometimes coercively, but sometimes also with some degree of legitimacy from the population.

In some states like Sinaloa, despite the operations to take out cartel’s leaders, the illicit economies are still extensive and profitable. But what’s more important is that levels of violence remain high and the population is still suffering deeply.

The day-to-day reality for people in some of these regions is still one of fear.

And in the greater scheme of things, criminal networks are still very powerful – they are embedded in the country’s economy and politics, and connect to communities in complex ways.

How does the El Mencho operation fit Mexico’s strategy on cartels?

The past two governments vowed to reduce the militarization of security forces. But the power of the military in Mexico has actually expanded.

The government of President Claudia Sheinbaum wanted a big, visible hit at a time when the U.S. is pushing for more militarized policies to counter Mexico’s trafficking organizations.

But this dynamic is not new. Most U.S. and Mexican policy regarding drug trafficking organizations has historically emphasized these high-profile captures – even if it is just for short-term gains.

It’s easier to say “we captured a drug lord” than address broader issues of corruption or impunity. Most of the time when these cartel leaders are captured or killed, there is generally no broader justice. It isn’t accompanied with authorities investigating disappearances, murders, corruption or even necessarily halting the flow of drugs.

Captures and killings of cartel leaders serve a strategic purpose of showing that something is being done, but the effectiveness of such policies in the long run is very limited.

Of course, taking out a drug lord is not a bad thing. But if it does not come with a broader dismantling of criminal networks and an accompanying focus on justice, then the main crimes that these groups commit – homicides, disappearances and extortion – will continue to affect the daily life of people. And the effect on illicit flows is, at best, meager.

Angélica Durán-Martínez has received funding from the Harry Frank Guggenheim Foundation, the Social Science Research Funding and the United States Institute of Peace.

– ref. Violent aftermath of Mexico’s ‘El Mencho’ killing follows pattern of other high-profile cartel hits – https://theconversation.com/violent-aftermath-of-mexicos-el-mencho-killing-follows-pattern-of-other-high-profile-cartel-hits-276728

Source: The Conversation – Global Perspectives – By John (Eddie) La Marca, Senior Research Officer, Blood Cells and Blood Cancer, WEHI (Walter and Eliza Hall Institute of Medical Research)

If you’re feeling worn out or have suddenly lost some weight, your doctor might send you for a blood test.

Blood tests are a common way health-care professionals detect, diagnose, and monitor a range of medical conditions.

But can they help us detect more serious conditions such as cancer? Let’s dive into the research.

How do blood tests work?

Blood tests are a technique used in the field of pathology, which is the study of the nature and causes of disease.

Blood tests assess what cells, proteins, and molecules are present in the blood. Health-care professionals use them to monitor things like organ health, nutrition levels, immune system function, and the presence of some infections.

To test for anaemia, for example, you would take a blood test and count the number of red blood cells in that blood sample. Another example is blood sugar testing, which is used to measure the glucose levels of a patient with diabetes.

What can blood tests tell us about cancer?

Currently, we can’t reliably diagnose most cancers using a blood test. One major reason is it’s often difficult to distinguish between cancer cells and normal, healthy cells. This is especially true when it comes to early-stage tumours.

But blood test results can give us clues about whether certain cancers are present in the body. So how do they do this?

1. By revealing abnormalities in your blood

Blood cancers will often cause clear changes in the number and types of cells in the bloodstream. We can measure these changes using a complete blood count, also known as a “full blood examination”.

This type of blood test counts all the different types of cells present in the blood: red blood cells, white blood cells, platelets, and more. Blood cancers arise when your body produces an abnormal amount of any type of blood cell. White blood cells, which fight infection, are the most common example. So a high number of one or more of these cell types may suggest the presence of a blood cancer.

But complete blood counts aren’t enough to make a conclusive diagnosis of blood cancer. We need to perform other tests to confirm whether the problem is a cancer or a different disease. These tests may include a biopsy or imaging techniques such as an MRI, CT scan, or X-ray.

2. By identifying “tumour markers”

We can also use blood tests to detect specific proteins which cancer cells often produce in greater numbers. These proteins are known as “tumour markers”.

One example of a tumour marker is prostate-specific antigen. This antigen is a protein made exclusively by the prostate gland. A healthy male will have only a small amount of prostate-specific antigen in his blood. In contrast, a male with prostate cancer will often produce abnormally high levels of this antigen. In this way, the prostate-specific antigen can serve as a “marker” of prostate cancer.

There are many different tumour markers used to identify different cancers. However, measuring tumour markers is not a foolproof solution. This is because they can be influenced by other factors. For example, an injury to or inflammation of the prostate gland could cause prostate-specific antigen levels to increase. So your doctor may perform additional tests to confirm if a person has cancer.

---

Read more:
Do I have prostate cancer? Why a simple PSA blood test alone won’t give you the answer

---

3. By locating rogue cells

For other types of cancer, blood tests can look for circulating tumour cells. Circulating tumour cells are produced when cancer cells break off from the original tumour and then enter the bloodstream. This usually only happens when a cancer reaches a more advanced stage and is metastatic, meaning it has spread to other parts of the body.

But this type of test is usually prognostic, rather than diagnostic. This means we can only use it to monitor the progression of a cancer which has already been diagnosed. So if a blood test does identify circulating tumour cells, it is best to conduct additional tests before proceeding with treatment.

So, are we close to creating a cancer-detecting blood test?

Unfortunately, we are yet to find a way to detect cancer with a single blood test. It’s a very difficult task, but researchers are making progress.

Circulating tumour DNA is a current topic of interest. These DNA molecules have mutations which distinguish them from healthy cells and can give information about the cancer they came from.

In one 2025 trial, Australian researchers measured the amount of circulating tumour DNA in 441 people with colon cancer to determine which patients would respond to chemotherapy. Another study from 2025 used circulating tumour DNA to monitor how 940 patients with lung cancer responded to different treatments.

One test did claim to successfully use circulating tumour DNA to detect more than 50 types of early-stage cancer. It’s known as the “Galleri test” and was first trialled in the UK in 2021. However, some experts have since raised concerns about the test’s effectiveness.

Researchers are also exploring other ways of using blood tests. In one 2025 study, Australian researchers adapted an existing test to use blood instead of tissue samples to identify known markers of ovarian cancer.

Another Australian study from 2025 investigated whether molecules other than proteins could serve as cancer markers. It found certain fats in blood can indicate if a patient with advanced prostate cancer will respond to treatment.

So, it looks like we’re still a while away from creating a cancer-detecting blood test. But with some time, effort, and robust research, it could be a possibility.

John (Eddie) La Marca receives funding from Cancer Council Victoria. He is affiliated with the Olivia Newton-John Cancer Research Institute and the Walter and Eliza Hall Institute of Medical Research.

Cameron Lewis receives funding from the University of Melbourne as part of a PhD scholarship. He is employed by Austin Health as a clinical haematologist.

Sarah Diepstraten receives funding from the National Health and Medical Research Council, Cure Cancer Australia and My Room Children’s Cancer Charity.

– ref. Can blood tests really detect cancer? – https://theconversation.com/can-blood-tests-really-detect-cancer-269906

Source: The Conversation – Global Perspectives – By Felicity Goodyear-Smith, Professor of General Practice and Primary Health Care, University of Auckland, Waipapa Taumata Rau

Primary care – the kind delivered by general practice (GP) clinics – is the backbone of every health system. When it works, we barely notice it.

It keeps people healthy, detects problems early, coordinates care and keeps people out of hospital.

But across many high-income countries, despite very different health systems, primary care is under unprecedented strain.

Our recently published paper presents case studies from the United Kingdom, the Netherlands, Canada, the United States, Australia and New Zealand.

All show governments are leaning on primary care to solve increasingly complex health needs. At the same time, bureaucracies are demanding more documentation, compliance, performance metrics and administrative work.

However, very little new investment is going into the four parts of primary care that matter most:

• continuity: seeing the same health provider over time, rather than pinballing from one specialist to another

• comprehensiveness: getting the whole family’s physical, mental and social health care from one place

• coordination: ensuring all the different people and services involved in a patient’s care work together smoothly, information is shared and roles are clear, so patients don’t fall through the cracks

• first-contact care: being able to get an appointment with a doctor or nurse you know, when you need it.

Ballooning administrative burdens

These are the core functions of effective primary care, and they are what reduce hospital visits. But across many countries, the GP workforce is shrinking or stagnating just as populations are ageing and multi-morbidity is increasing.

Medical graduates are turning away from general practice, citing high workloads, lower pay relative to other specialities, and the emotional weight of increasingly complex care.

Many GPs who stay in practice are reducing their hours, not because they lack commitment, but because the amount of unpaid work required outside of the consulting room makes full-time practice untenable.

Administrative burdens have ballooned. Electronic health-record systems generate endless inbox tasks. As hospitals push chronic care back into the community, GPs absorb more responsibility without receiving the resources to match.

The result is predictable: practices stop enrolling new patients, waiting times blow out, and people who cannot get timely care turn instead to emergency departments.

These alternatives are often far more expensive, lack continuity, and do not offer the long-term relationships that help detect disease early and manage chronic conditions effectively.

Quick wins, long-term losses

Many of the countries facing these problems spend less than 6% of their total health budget on primary care. For example, the US spends 4%, New Zealand 5.4% and Australia 6%. But how the money is allocated is as important as the amount itself.

Funding models in many countries fail to support team-based care – a collaborative, coordinated model of healthcare delivery in which multiple health professionals work together with patients and their families.

Governments often finance new roles – for example, physician assistants – in isolation, without ensuring practices have the infrastructure to integrate them safely and effectively. This creates inefficiencies and fragmentation.

Poorly designed “pay-for-performance” measures can make things worse. So, when funding is linked to disease-specific indicators rather than the core functions of high-quality primary care, clinicians end up spending more time on documentation and less on patients.

Continuity and comprehensiveness, the strongest predictors of better health outcomes, remain largely unmeasured and unrewarded.

The benefits of primary care investment accumulate slowly – fewer hospital admissions, better management of chronic disease, reduced premature mortality. But political cycles reward quick wins. Governments are tempted to fund initiatives that reduce waiting lists in months, not strengthen foundations for decades.

The result is a proliferation of short-term “solutions” that crowd out the long-term reforms primary care actually needs. The system that prevents downstream costs is neglected because its benefits are not immediately visible.

Toward a sustainable health system

Primary care is relationship-based. That continuity – knowing patients, their histories, their families and the context of their lives – is what allows efficient decision-making and prevents unnecessary interventions.

When investment flows into standalone or narrow services instead of strengthening general practice, care becomes episodic. This can result in poor followup and patients bouncing between providers who are working without shared information.

This fragmentation increases costs while reducing quality, even though each individual initiative may look beneficial in isolation. Once the foundation cracks, the entire system becomes more expensive to maintain but less effective.

The solutions are clear, and are strikingly consistent across countries. A whole-of-system approach is needed to:

• set explicit investment targets for primary care

• align funding, workforce planning and service delivery

• invest in true multidisciplinary teams, not piecemeal roles

• prioritise continuity, comprehensiveness, and first-contact access in funding models

• and create long-term accountability structures that survive election cycles.

Countries that have strong primary care systems will spend less overall on health, have better population health outcomes, and enjoy greater equity. Those that neglect primary care pay for it many times over in hospital pressures, workforce burnout and widening inequities.

Strengthening primary care is not just another reform. It is the only path to a sustainable health system. Countries that fail to recognise this are already seeing the consequences.

Felicity Goodyear-Smith has received funding from the NZ Health Research Council, the Bill and Melinda Gates Foundation, the Ministry of Business, Innovation & Employment, and other NZ research funding bodies.

– ref. We studied primary care in 6 rich countries – it’s under unprecedented strain everywhere – https://theconversation.com/we-studied-primary-care-in-6-rich-countries-its-under-unprecedented-strain-everywhere-276617

Source: The Conversation – Global Perspectives – By Sara Webb, Lecturer, Centre for Astrophysics and Supercomputing, Swinburne University of Technology

One of the largest known stars in the universe underwent a dramatic transformation in 2014, new research shows, and may be preparing to explode.

A study led by Gonzalo Muñoz-Sanchez at the National Observatory of Athens, published in Nature Astronomy today, argues that the enormous star WOH G64 has transitioned from a red supergiant to a rare yellow hypergiant – in what may be evidence of impending supernova.

The evidence suggests we may be witnessing, in real time, a massive star shedding its outer layers, shrinking as it heats up, and moving closer to the end of its short life.

A very special star

WOH G64 was first discovered in the 1970s as as star of interest in the Large Magellanic Cloud, a dwarf galaxy orbiting the Milky Way.

It turned out the star was not only extremely luminous, but also one of the biggest ever discovered: more than 1,500 times the radius of the Sun.

In 2024, WOH G64 was the first star beyond our galaxy ever photographed in detail, thanks to the Very Large Telescope Interferometer. The image showed a clear dusty cocoon around the central giant star, which confirmed it was losing mass as it aged.

From supergiant to hypergiant, big is big

WOH G64 is a young star in the grand scheme of the cosmos, with an estimated age of less than 5 million years old. Unlike our Sun (currently about 4.6 billion years old), WOH G64 is destined to live fast and die young.

WOH G64 was born big, forming from a huge cloud of gas and dust collapsing until the pressure made it ignite. Like our Sun, it would have burned hydrogen in its core by nuclear fusion.

Later it would have expanded and burned helium, becoming what is called a red supergiant.

Not all supergiants become hypergiants. It’s been theorised that hypergiants form when very large stars quickly burn and evolve from burning hydrogen to burning helium.

During this transition, these stars start to shed their outer layers, while their cores begin to shrink inwards. Once a star becomes a hypergiant, it is destined for a quick death in the fiery explosion of a supernova.

What has caused this change seen in WOH G64?

So what happened to WOH G64 in 2014? The new study proposes that a large part of the original supergiant’s surface was ejected away from the star.

This may have been due to interactions with a companion star, which the authors have confirmed exists by looking at the spectrum of light from WOH G64.

Another theory: the star is getting ready to explode. We know stars this big will inevitably go kaboom, but exactly when it will happen can be hard to determine in advance.

One possible scenario is that the transition we’re seeing is due to a pre-supernova “superwind” phase. This is theorised to occur due to strong internal pulsations as the fuel in the core is spent quickly.

Only time will tell

Most stars live for tens of millions or even tens of billions of years. It was never a given we would witness and be able to document so much transformation in a star, let alone one outside our galaxy.

If we are lucky, we will see the death of WOH G64 in our lifetimes – not only providing an incredible intergalactic spectacle but also helping scientists complete the puzzle of this fascinating star.

Sara Webb does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

– ref. One of the biggest stars in the universe might be getting ready to explode – https://theconversation.com/one-of-the-biggest-stars-in-the-universe-might-be-getting-ready-to-explode-276519